Biosig Technologies, Common Stock Current Valuation
| BSGM Stock | USD 1.34 0.04 3.08% |
Valuation analysis of BioSig Technologies, helps investors to measure BioSig Technologies,'s intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that BioSig Technologies,'s price fluctuation is out of control at this time. Calculation of the real value of BioSig Technologies, is based on 3 months time horizon. Increasing BioSig Technologies,'s time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the BioSig otc stock is determined by what a typical buyer is willing to pay for full or partial control of BioSig Technologies, Common. Since BioSig Technologies, is currently traded on the exchange, buyers and sellers on that exchange determine the market value of BioSig OTC Stock. However, BioSig Technologies,'s intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.34 | Real 1.03 | Hype 1.3 | Naive 1.61 |
The intrinsic value of BioSig Technologies,'s stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence BioSig Technologies,'s stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of BioSig Technologies, Common helps investors to forecast how BioSig otc stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of BioSig Technologies, more accurately as focusing exclusively on BioSig Technologies,'s fundamentals will not take into account other important factors: BioSig Technologies, Common OTC Stock Current Valuation Analysis
BioSig Technologies,'s Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current BioSig Technologies, Current Valuation | 6.43 M |
Most of BioSig Technologies,'s fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BioSig Technologies, Common is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, BioSig Technologies, Common has a Current Valuation of 6.43 M. This is 99.96% lower than that of the Health Care Equipment & Supplies sector and 99.95% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.96% higher than that of the company.
BioSig Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BioSig Technologies,'s direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of BioSig Technologies, could also be used in its relative valuation, which is a method of valuing BioSig Technologies, by comparing valuation metrics of similar companies.BioSig Technologies, is currently under evaluation in current valuation category among its peers.
BioSig Fundamentals
| Return On Equity | -59.77 | ||||
| Return On Asset | -4.48 | ||||
| Operating Margin | (227.43) % | ||||
| Current Valuation | 6.43 M | ||||
| Shares Outstanding | 14.12 M | ||||
| Shares Owned By Insiders | 17.59 % | ||||
| Shares Owned By Institutions | 3.04 % | ||||
| Number Of Shares Shorted | 461.7 K | ||||
| Price To Earning | (3.73) X | ||||
| Price To Book | 36.58 X | ||||
| Price To Sales | 90.04 X | ||||
| Revenue | 18 K | ||||
| Gross Profit | 242 K | ||||
| EBITDA | (28.15 M) | ||||
| Net Income | (28.69 M) | ||||
| Cash And Equivalents | 887 K | ||||
| Cash Per Share | 0.02 X | ||||
| Total Debt | 452 K | ||||
| Debt To Equity | 0.45 % | ||||
| Current Ratio | 1.22 X | ||||
| Book Value Per Share | (0.39) X | ||||
| Cash Flow From Operations | (17.31 M) | ||||
| Short Ratio | 0.95 X | ||||
| Earnings Per Share | (0.86) X | ||||
| Target Price | 6.0 | ||||
| Beta | 0.84 | ||||
| Market Capitalization | 6.64 M | ||||
| Total Asset | 1.8 M | ||||
| Retained Earnings | (245.01 M) | ||||
| Working Capital | (4.05 M) | ||||
| Current Asset | 984.54 K | ||||
| Current Liabilities | 2.47 M | ||||
| Net Asset | 1.8 M |
About BioSig Technologies, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BioSig Technologies, Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioSig Technologies, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioSig Technologies, Common based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in BioSig OTC Stock
BioSig Technologies, financial ratios help investors to determine whether BioSig OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BioSig with respect to the benefits of owning BioSig Technologies, security.